PhaseBio

@PhaseBio

PhaseBio is focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications.

Malvern, PA and San Diego, CA
Vrijeme pridruživanja: listopad 2018.

Tweetovi

Blokirali ste korisnika/cu @PhaseBio

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @PhaseBio

  1. 4. velj

    announces case study highlighting hemodynamic data that supports the potential of PB1046, a once-weekly VIP analogue for adults with pulmonary arterial hypertension and was presented at the 14th PVRI World Congress.

    Poništi
  2. 13. sij

    announces acquisition of novel oral aldosterone synthase inhibitor to develop for treatment-resistant .

    Poništi
  3. 10. sij

    Today, we announced a financing and co-development collaboration with SFJ Pharmaceuticals® for PB2452.

    Poništi
  4. 13. pro 2019.

    Want to learn more about ? Check out this podcast to learn more about PB1046, a once weekly treatment we are developing for adults struggling with .

    Poništi
  5. 12. pro 2019.

    Dr. Harold Palevsky discusses once-weekly VIP analogue PB1046 that is currently in clinical trials for adults struggling with . Listen to the podcast here.

    Poništi
  6. 11. pro 2019.

    Cardiologist Dr. Raymond Benza discusses and once weekly VIP analogue PB1046 currently in clinical trials for adults with . Listen to the podcast here.

    Poništi
  7. 11. pro 2019.

    Have you heard pulmonologist Dr. Harold Palevsky discuss once weekly VIP analogue PB1046 that is currently in clinical trials for adults struggling with ? Listen to the podcast here.

    Poništi
  8. 10. pro 2019.

    Thank you for another educational meeting. looks forward to and sharing updates on PB2452, a novel reversal agent for the drug .

    Poništi
  9. 9. pro 2019.

    Listen to the latest “I’m Aware That I’m Rare” phaware podcast that talks about our once weekly VIP analogue PB1046 for adult patients struggling with pulmonary arterial hypertension.

    Poništi
  10. 9. pro 2019.

    We are in Orlando for and looking forward to hearing the latest scientific updates from . Want to know more about us, including our work to develop a novel reversal agent for the drug ? Check out

    Poništi
  11. 7. pro 2019.

    is developing a novel reversal agent for the drug ? Learn more about PB2452:

    Poništi
  12. 6. pro 2019.

    Missed yesterday’s podcast about adult patients struggling with Dr. Palevsky? Check out the transcript here.

    Poništi
  13. proslijedio/la je Tweet
    5. pro 2019.

    Dr. Harold Palevsky discusses a new molecule on the forefront of treatment for pulmonary arterial hypertension called PB1046 and the positive effects it could have for the PAH community. podcast ep 305  

    Poništi
  14. 4. pro 2019.

    Stay tuned for an upcoming podcast featuring pulmonologist Dr. Harold Palevsky discussing adult patients struggling with going live on Thursday, 12/5.

    Poništi
  15. 2. pro 2019.

    Have you heard cardiologist Dr. Raymond Benza discuss long-acting VIP analogue PB1046 for adults struggling with ? Listen to the podcast here.

    Poništi
  16. 30. stu 2019.

    Listen to the latest podcast to learn more about long-acting VIP analogue PB1046 for adults struggling with .

    Poništi
  17. 29. stu 2019.
    Poništi
  18. proslijedio/la je Tweet
    28. stu 2019.

    Dr. Raymond Benza discusses the importance of in patients with pulmonary arterial hypertension including a new molecule that's on the forefront of treatment for PAH called PB1046. podcast 303  

    Poništi
  19. 27. stu 2019.

    Learn more about PB1046, a once-weekly treatment we are developing for adults struggling with .

    Poništi
  20. 26. stu 2019.

    Stay tuned for an upcoming podcast featuring cardiologist Dr. Raymond Benza discussing going live on Thursday, 11/28.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·